Overview
| Product name | Recombinant Human Lp-PLA2/PLA2G7 Protein |
|---|
| Catalog No. | RP02875 |
|---|
| Description | Recombinant Human Lp-PLA2/PLA2G7 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Phe22-Asn441) of human Lp-PLA2/PLA2G7 (Accession #NP_001161829.1) fused with a His tag at the C-terminus. |
|---|
| Purity | > 97% by SDS-PAGE. |
|---|
| Endotoxin | <1EU/μg of the protein by LAL method. |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of 50mM NaAc, 150mM NaCl, 10% glycerol (pH 5.0) |
|---|
| Species | Human |
|---|
| Calculated MW | 48.63 kDa |
|---|
Background
Platelet-activating factor acetylhydrolase, also known as 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycero-phosphocholine esterase, Group-VIIA phospholipase A2, LDL-associated phospholipase A2, PAF 2-acylhydrolase, PLA2G7 and PAFAH, is a secreted protein that belongs to the AB hydrolase superfamily and Lipase family. PLA2G7 / PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7 / PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes, including cardiovascular disease. PLA2G7 also represents an important, potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait that is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.
Product information
| Synonym | PLA2G7; LDL-PLA2; LP-PLA2; PAFAD; PAFAH |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
